Home/Pipeline/Gene Delivery platform

Gene Delivery platform

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Omios Biologics

About Omios Biologics

Omios Biologics is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company's core innovation is a patented oncolytic vaccinia virus platform designed with a built-in biomarker for selectivity, aiming to overcome the efficacy-safety trade-offs of earlier OV therapies. With a leadership team possessing deep expertise in virology and biotech, Omios is developing a pipeline of OV therapies, cancer vaccines, and gene delivery vectors, targeting a significant market opportunity in oncology with a focus on combination treatments.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed